ArticleRespirology case reports2025
Lung Adenocarcinoma With Extensive Vascular Invasion and Retinal Metastasis: A Case Report.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Retinal metastasis from lung adenocarcinoma: a case report.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 34-year-old Ghanaian male with no past medical history presented to our hospital with dyspnoea, left-sided chest pain, and left-eye visual disturbance. Imaging revealed a large mediastinal mass with vascular invasion, left pleural and skeletal metastases. A lung biopsy confirmed lung adenocarcinoma (LUAD) with mixed solid and lepidic growth patterns, showing 80% PD-L1 expression. Positron emission tomography (PET) identified a highly active lesion in the left eye, suggestive of retinal metastasis. Ophthalmologic evaluation confirmed retinal involvement. Given ROS1 positivity, Crizotinib was initially prescribed but switched to Lorlatinib due to concerns regarding retinal involvement. The patient demonstrated rapid clinical improvement, including notable visual recovery, with stable performance status after 1 month. This case underscores LUAD's potential for atypical metastasis, such as to the retina, necessitating comprehensive assessment and personalised management strategies. The shift from Crizotinib to Lorlatinib highlights the importance of targeted therapy in managing advanced NSCLC with rare metastatic involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.